Scienture Holdings, Inc.(SCNX)Earnings, Financials & Key RatiosScienture Holdings, Inc. (SCNX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to generate positive operating income over the last ten quarters and the massive $102.3 million in stock-based compensation in 2026Q1 suggest a fundamentally unviable business model.
Scienture Holdings, Inc. (SCNX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Scienture Holdings, Inc. (SCNX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.08vs $0.23+65.2% | $56,325vs $400,983-86.0% |
| Q2 2026 | Mar 24, 2026 | $1.76vs $0.22-700.0% | $168,699vs $486,415-134.7% |
| Q4 2025 | Nov 12, 2025 | $0.19 | $590,050 |
| Q3 2025 | Aug 12, 2025 | $0.48 | — |
Recent stock market news and headlines for Scienture Holdings, Inc. (SCNX)
Broader pharmacy access, channel expansion, and payer coverage position Arbli ™ for increased prescription volume and revenue growth
Key metrics vs top competitors for Scienture Holdings, Inc. (SCNX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.35 | $140.34M | -0.13 | 215.87% | -9618.03% | -0.12% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $60.89 | $2.62B | -38.30 | 146.71% | -9.02% | -14.19% | — | |
| $123.72 | $9.1B | -21.15 | — | — | -42.78% | — | |
| $1.54 | $33.77M | -0.47 | — | — | -1335.64% | — | |
| $38.02 | $1.04B | -223.65 | 104.94% | -1.7% | -5.68% | — |
Scienture Holdings, Inc. (SCNX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Scienture Holdings, Inc. (SCNX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
May 1, 2026·SEC
Nov 18, 2025·SEC
Get notified when SCNX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Scienture Holdings, Inc. (SCNX) stock FAQ — growth, dividends, profitability & financials explained
Scienture Holdings, Inc. (SCNX) reported $0.5M in revenue for fiscal year 2025.
Scienture Holdings, Inc. (SCNX) grew revenue by 215.9% over the past year. This is strong growth.
Scienture Holdings, Inc. (SCNX) reported a net loss of $41.9M for fiscal year 2025.
Scienture Holdings, Inc. (SCNX) has a return on equity (ROE) of -0.1%. Negative ROE indicates the company is unprofitable.
Scienture Holdings, Inc. (SCNX) had negative free cash flow of $2.93B in fiscal year 2025, likely due to heavy capital investments.
